Prof Marion Subklewe speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about using T cell recruiting antibody constructs for the treatment of AML.
She explains that so far T cell recruiting antibodies have been used to target surface antigens, but these have the limitation of not having a restricted expression profile.
To solve this problem, Prof Subklewe explains that they have been doing preclinical work with a novel T cell recruiting antibody construct which recognises an infracellular target antigen - WT1 - and so has a much more specific and restricted target antigen.
Prof Subklewe concludes by saying that she hopes this promising new information leads to a phase I trial.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.